{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T09:20:40Z","timestamp":1781601640375,"version":"3.54.5"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T00:00:00Z","timestamp":1667347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T00:00:00Z","timestamp":1667347200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Chronic inflammatory demyelinating polyneuropathy (CIDP) is an autoimmune disease that involves damage to the peripheral nervous system. The course of the disease can progress for more than 8\u00a0weeks, with frequent incidences of relapse-remission courses. This article reported a rare combination of CIDP with fluctuating symptoms, recurrence-remission, and comorbidity with psoriasis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>A 29-year-old male patient with repeated limb weakness and numbness was admitted to the hospital several times in the past six months. He had a history of psoriasis for 6\u00a0years, and the medications (clobetasol propionate ointment and calcipotriol ointment) treated for psoriasis were discontinued 1\u00a0year ago. During the hospitalization, repeated intravenous injections of human immunoglobulin G (IVIg), immunoadsorption, and secukinumab were performed. Nerve electrophysiology tests, ganglioside autoantibody spectrum tests, and clinical MRC muscle strength scores were performed on a regular basis to confirm the diagnosis of CIDP. The patient was regularly followed up.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>After repeated rounds of human IVIg and immunoadsorption, the patient\u2019s MRC score was increased by\u2009\u2265\u20096 points. The first ganglioside autoantibody spectrum test showed anti-GQ1b IgG (\u2009+) and anti-GM1 IgM (\u2009+) antibodies, and all were negative after re-examination. Finally, the patient was treated with the IL-17A inhibitor secukinumab for psoriasis. During 7\u00a0months of follow-up, the CIDP and psoriasis symptoms are relatively stable.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Combination of IVIg and immunoadsorption was highly effective in treating CIDP complicated with psoriasis. The clinical manifestations of CIDP are diverse. When relapse-remission occurs in the course of the disease, it is necessary to clarify whether it is combined with other autoimmune diseases and should control the autoimmune diseases as soon as possible.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12883-022-02928-3","type":"journal-article","created":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T05:02:29Z","timestamp":1667365349000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Chronic inflammatory demyelinating polyneuropathy and psoriasis comorbidity with significantly alleviated in symptoms after secukinumab: case report"],"prefix":"10.1186","volume":"22","author":[{"given":"Yan","family":"Jin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjuan","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoquan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongdong","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4017-4529","authenticated-orcid":false,"given":"Zuneng","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,2]]},"reference":[{"issue":"3","key":"2928_CR1","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/jns.12455","volume":"26","author":"PYK Van den Bergh","year":"2021","unstructured":"Van den Bergh PYK, van Doorn PA, Hadden RDM, Avau B, Vankrunkelsven P, Allen JA, et al. European Academy of Neurology\/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force-Second revision. J Peripher Nerv Syst. 2021;26(3):242\u201368. https:\/\/doi.org\/10.1111\/jns.12455.","journal-title":"J Peripher Nerv Syst"},{"issue":"8","key":"2928_CR2","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/s1474-4422(19)30144-9","volume":"18","author":"C Bunschoten","year":"2019","unstructured":"Bunschoten C, Jacobs BC, Van den Bergh PYK, Cornblath DR, van Doorn PA. Progress in diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy. The Lancet Neurology. 2019;18(8):784\u201394. https:\/\/doi.org\/10.1016\/s1474-4422(19)30144-9.","journal-title":"The Lancet Neurology"},{"key":"2928_CR3","doi-asserted-by":"publisher","unstructured":"Rendon A, Schakel K. Psoriasis Pathogenesis and Treatment. Int J Mol Sci. 2019;20 6; doi: https:\/\/doi.org\/10.3390\/ijms20061475.","DOI":"10.3390\/ijms20061475"},{"issue":"9583","key":"2928_CR4","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/s0140-6736(07)61128-3","volume":"370","author":"CEM Griffiths","year":"2007","unstructured":"Griffiths CEM, Barker JNWN. Pathogenesis and clinical features of psoriasis. The Lancet. 2007;370(9583):263\u201371. https:\/\/doi.org\/10.1016\/s0140-6736(07)61128-3.","journal-title":"The Lancet"},{"issue":"9997","key":"2928_CR5","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/s0140-6736(14)61909-7","volume":"386","author":"W-H Boehncke","year":"2015","unstructured":"Boehncke W-H, Sch\u00f6n MP. Psoriasis. The Lancet. 2015;386(9997):983\u201394. https:\/\/doi.org\/10.1016\/s0140-6736(14)61909-7.","journal-title":"The Lancet"},{"issue":"14","key":"2928_CR6","doi-asserted-by":"publisher","first-page":"879","DOI":"10.2169\/internalmedicine.45.1704","volume":"45","author":"Y Taguchi","year":"2006","unstructured":"Taguchi Y, Takashima S, Yoshida S, Dougu N, Inoue H, Tanaka K. Psoriasis improved by intravenous immunoglobulin therapy. Intern Med. 2006;45(14):879\u201380. https:\/\/doi.org\/10.2169\/internalmedicine.45.1704.","journal-title":"Intern Med"},{"issue":"1","key":"2928_CR7","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1111\/bjd.12572","volume":"170","author":"AC Foulkes","year":"2014","unstructured":"Foulkes AC, Wheeler L, Gosal D, Griffiths CE, Warren RB. Development of chronic inflammatory demyelinating polyneuropathy in a patient receiving infliximab for psoriasis. Br J Dermatol. 2014;170(1):206\u20139. https:\/\/doi.org\/10.1111\/bjd.12572.","journal-title":"Br J Dermatol"},{"issue":"4","key":"2928_CR8","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1684\/ejd.2016.2781","volume":"26","author":"M Nakao","year":"2016","unstructured":"Nakao M, Asano Y, Nakamura K, Shida R, Takahashi T, Yoshizaki A, et al. The development of chronic inflammatory demyelinating polyneuropathy during adalimumab treatment in a patient with psoriasis vulgaris. Eur J Dermatol. 2016;26(4):404\u20135. https:\/\/doi.org\/10.1684\/ejd.2016.2781.","journal-title":"Eur J Dermatol"},{"key":"2928_CR9","doi-asserted-by":"publisher","unstructured":"Ahmed Z, Powell R, Llewelyn G, Anstey A. Chronic inflammatory demyelinating polyradiculoneuropathy complicating anti TNF alpha therapy for chronic plaque psoriasis. BMJ Case Rep. 2011;2011; doi: https:\/\/doi.org\/10.1136\/bcr.08.2011.4674.","DOI":"10.1136\/bcr.08.2011.4674"},{"issue":"1","key":"2928_CR10","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.tem.2017.10.010","volume":"29","author":"J Vandewalle","year":"2018","unstructured":"Vandewalle J, Luypaert A, De Bosscher K, Libert C. Therapeutic Mechanisms of Glucocorticoids. Trends Endocrinol Metab. 2018;29(1):42\u201354. https:\/\/doi.org\/10.1016\/j.tem.2017.10.010.","journal-title":"Trends Endocrinol Metab"},{"issue":"9","key":"2928_CR11","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1136\/jnnp-2019-320314","volume":"90","author":"HC Lehmann","year":"2019","unstructured":"Lehmann HC, Burke D, Kuwabara S. Chronic inflammatory demyelinating polyneuropathy: update on diagnosis, immunopathogenesis and treatment. J Neurol Neurosurg Psychiatry. 2019;90(9):981\u20137. https:\/\/doi.org\/10.1136\/jnnp-2019-320314.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2928_CR12","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jaut.2019.04.021","volume":"102","author":"Y Rodriguez","year":"2019","unstructured":"Rodriguez Y, Vatti N, Ramirez-Santana C, Chang C, Mancera-Paez O, Gershwin ME, et al. Chronic inflammatory demyelinating polyneuropathy as an autoimmune disease. J Autoimmun. 2019;102:8\u201337. https:\/\/doi.org\/10.1016\/j.jaut.2019.04.021.","journal-title":"J Autoimmun"},{"key":"2928_CR13","doi-asserted-by":"publisher","unstructured":"Dorst J, Fillies F, Dreyhaupt J, Senel M, Tumani H. Safety and Tolerability of Plasma Exchange and Immunoadsorption in Neuroinflammatory Diseases. J Clin Med. 2020;9 9; doi: https:\/\/doi.org\/10.3390\/jcm9092874.","DOI":"10.3390\/jcm9092874"},{"issue":"1","key":"2928_CR14","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41572-018-0027-2","volume":"4","author":"BC Kieseier","year":"2018","unstructured":"Kieseier BC, Mathey EK, Sommer C, Hartung HP. Immune-mediated neuropathies Nat Rev Dis Primers. 2018;4(1):31. https:\/\/doi.org\/10.1038\/s41572-018-0027-2.","journal-title":"Immune-mediated neuropathies Nat Rev Dis Primers"},{"issue":"4","key":"2928_CR15","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1111\/bjd.18245","volume":"182","author":"NJ Korman","year":"2020","unstructured":"Korman NJ. Management of psoriasis as a systemic disease: what is the evidence? Br J Dermatol. 2020;182(4):840\u20138. https:\/\/doi.org\/10.1111\/bjd.18245.","journal-title":"Br J Dermatol"},{"issue":"4","key":"2928_CR16","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1111\/j.1529-8027.2010.00294.x","volume":"15","author":"LJ Chi","year":"2010","unstructured":"Chi LJ, Xu WH, Zhang ZW, Huang HT, Zhang LM, Zhou J. Distribution of Th17 cells and Th1 cells in peripheral blood and cerebrospinal fluid in chronic inflammatory demyelinating polyradiculoneuropathy. J Peripher Nerv Syst. 2010;15(4):345\u201356. https:\/\/doi.org\/10.1111\/j.1529-8027.2010.00294.x.","journal-title":"J Peripher Nerv Syst"},{"key":"2928_CR17","doi-asserted-by":"publisher","unstructured":"Wolbert J, Cheng MI, Meyer zu Horste G, Su MA. Deciphering immune mechanisms in chronic inflammatory demyelinating polyneuropathies. JCI Insight. 2020;5 3; doi: https:\/\/doi.org\/10.1172\/jci.insight.132411.","DOI":"10.1172\/jci.insight.132411"},{"key":"2928_CR18","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/1742-2094-11-63","volume":"11","author":"M Stettner","year":"2014","unstructured":"Stettner M, Lohmann B, Wolffram K, Weinberger JP, Dehmel T, Hartung HP, et al. Interleukin-17 impedes Schwann cell-mediated myelination. J Neuroinflammation. 2014;11:63. https:\/\/doi.org\/10.1186\/1742-2094-11-63.","journal-title":"J Neuroinflammation"},{"issue":"5","key":"2928_CR19","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1136\/annrheumdis-2020-218808","volume":"80","author":"X Baraliakos","year":"2021","unstructured":"Baraliakos X, Gossec L, Pournara E, Jeka S, Mera-Varela A, D\u2019Angelo S, et al. Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial. Ann Rheum Dis. 2021;80(5):582\u201390. https:\/\/doi.org\/10.1136\/annrheumdis-2020-218808.","journal-title":"Ann Rheum Dis"},{"issue":"10235","key":"2928_CR20","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1016\/s0140-6736(20)30564-x","volume":"395","author":"IB McInnes","year":"2020","unstructured":"McInnes IB, Behrens F, Mease PJ, Kavanaugh A, Ritchlin C, Nash P, et al. Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial. The Lancet. 2020;395(10235):1496\u2013505. https:\/\/doi.org\/10.1016\/s0140-6736(20)30564-x.","journal-title":"The Lancet"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-022-02928-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-022-02928-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-022-02928-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T05:03:41Z","timestamp":1667365421000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-022-02928-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,2]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2928"],"URL":"https:\/\/doi.org\/10.1186\/s12883-022-02928-3","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,2]]},"assertion":[{"value":"5 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from the patient to publish this case, and approval for this study was provided by the Research Ethics Committee of Renmin Hospital of Wuhan University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for the publication of this case report, including any potentially identifiable images or data included in this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors report no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"400"}}